GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-beta

This work has been financed by the Instituto de Salud Carlos III, Spain (www.isciii.es) and Fondo Europeo de Desarrollo Regional (FEDER), from the European Union, through the research grants PI15/00794, PI18/00826, CPII15/00032 (P.A.), and PI15/02015 (F.M.). P.A. is supported by the Consejería de Salud, Junta de Andalucía through the contract “Nicolás Monardes” (C-0013-2018). A. B. C-G. was supported by the Ministerio de Ciencia y Tecnología, through the contract PEJ-2014-A-46314. This work was also supported by the Agencia Estatal de Investigación (AEI) [MICINN/Fondo Europeo de Desarrollo Regional (FEDER) (SAF-2016-75286-R to R.R.), ISCIII/FEDER [Miguel Servet Program (CPII16/00049 to R.R.), Sara Borrell Program (CD16/00103 to S-T.M.) and Consorcio CIBERONC (CB16/12/00390)]. For its collaboration, we want to acknowledge the Principado de Asturias BioBank (PT17/0015/0023), financed jointly by Servicio de Salud del Principado de Asturias, Instituto de Salud Carlos III and Fundación Bancaria Cajastur and integrated in the Spanish National Biobank Network.